Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)

NCT04508855 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-07-30

No results posted yet for this study

Summary

The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy

Conditions

Interventions

DRUG

Low molecular weight heparin

Switch from direct oral anticoagulants to low molecular weight heparin

Sponsors & Collaborators

  • Theagenio Cancer Hospital

    collaborator OTHER_GOV
  • AHEPA University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2023-08-31
Completion
2023-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04508855 on ClinicalTrials.gov